Skip to main content

Table 6 PSA bounce in literature

From: Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence

Authors

Pub

N

Median Follow-up (months)

Hormone Therapy (%)

EBRT

(%)

Bounce Def

Rate

(%)

Time to onset

(months)

Magnitude

(ng/ml)

Duration

(months)

Predictive factors

Aaltomaa [10]

2009

444

81.6

yes (18)

Yes (4)

≥ 0.2 ng/ml

13

19.2

1.4

--

Age < 65, risk group, PSA nadir < 0.5

Bostancic et al. [11]

2007

164

65

yes (37.2)

no

≥ 0.2 ng/ml

26.9

18.9

0.5

8.7

Age,125 I >103 Pd *

Cavanagh et al. [12]

2000

591

55

no

yes

≥ 0.2 ng/ml

35.8

24.8

--

--

NC

Ciezki et al. [13]

2006

162

73

yes (38.2)

no

≥ 0.2 ng/ml

46.3

15

--

--

Age < 70 *

Caloglu [26]

2010

820

58

Yes (22.2)

no

≥ 0.2 ng/ml

≥ 0.4

≥ 0.6

≥ 0.8

30.1

19.6

12.8

9.5

17.4

16.3

16.2

15.7

--

--

Age, N of PSAs

Critz et al. [27]

2003

1,011

72

no

all

≥ 0.1 ng/ml

41

18

0.4

9

Age

Crook et al. [14]

2007

275

44

no

no

≥ 0.2 ng/ml

40

15.6

0.76

6.8

Age *

Das et al. [15]

2002

186

33

no

yes (25.8)

≥ 15%

62

26.4

0.6

12

--

Kanai et al. [17]

2009

86

32

no

no

≥ 0.4 ng/ml

33

15

0.6

--

Age < 67, D90 > 180 Gy

Kuban et al. [18]

2006

2,693

63

no

no

≥ 0.2 ng/ml

17

--

0.9

14

--

Hinnen et al. [16]

2011

975

78 ¤

Yes (19)

no

≥ 0.2 ng/ml

32.3

19.2

--

--

--

Makarewicz et al * [19]

2006

71

32

no

Yes (100)

≥ 0.2 ng/ml

31

13.5

0.28

--

Age, i PSA, V200

McGrath et al [28]*

2009

191

48

Yes (46%)

no

≥ 0.1 ng/ml

≥ 0.2 ng/ml

≥ 0.4 ng/ml

≥ 2 ng/ml

44

34

21

3

--

0.2

0.3

0.6

2.6

15

--

--

25

--

Merrick et al. [20]

2003

218

46

no

yes (57.1)

≥ 0.2 ng/ml

23.9

16.3

0.9

16

Age, TNM, V150

PSA post brachy

Mitchell et al. [21]

2008

205

45

no

no

≥ 0.2 ng/ml

37

14.8

0.91

--

Age

Morita et al. [29]

2004

200

35

no

no

≥ 0.1 ng/ml

40

13

0.3

--

--

Patel et al. [22]

2004

295

38

yes (62.4)

no

≥ 0.2 ng/ml

28

19.4

0.5

--

Age < 65 *

Pickles et al. [30]

2006

449

48

yes (70)

no

all

84

13

--

--

--

Satoh et al. [24]

2008

388

--

no

no

≥ 0.1 ng/ml

≥ 0.4 ng/ml

≥ 35%

50.8

23.5

19.4

--

0.4

--

--

Stock et al. [25]

2003

373

48

no

no

≥ 0.1 ng/ml

≥ 0.4 ng/ml

≥ 35%

31

17

20

19.5

19.5

20.5

--

--

Age < 65, prostate volume > 35 cm3 (bounce > 0.4)*

Thompson [31]

2010

1,006

54

Yes (65.7%)

no

+2 then nadir ≤ 0.5 ng/ml

2.5

20.6

--

--

Age

Toledano et al. [32, 33]

2006

295

42

yes (42.4)

no

≥ 0.1 ng/ml

≥ 0.2 ng/ml

≥ 0.4 ng/ml

55

49

32

19

0.8

11.2

Age < 70, D90 > 200 Gy *

Zwahlen [34]

2010

194

60

no

no

≥ 0.2 ng/ml

≥ 0.4 ng/ml

≥ 15%

≥ 35%

50

34

11

9

14

14

16

15.5

05

0.8

1.9

2

12

13

18

21.5

Age

Mazeron (this study)

2012

198

64

no

no

≥ 0.1 ng/ml

≥ 0.2 ng/ml

≥ 0.4 ng/ml

≥ 15%

≥ 35%

48.5

35.9

25.8

52

36.4

17

0.6

14

Age, PSA 6 weeks

  1. *: series including patients treated with HDR brachytherapy. --: non reported in publication. ¤: mean Abbreviations: Pub year = date of publication; N = number of patients; F-up, follow-up; Hormon, hormonal therapy. i PSA: pre treatment value of PSA. N of PSA: amount of PSA values recorded per patient